Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 we » 2 e (Expand Search), 2 de (Expand Search), _ we (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 we » 2 e (Expand Search), 2 de (Expand Search), _ we (Expand Search)
-
541
-
542
Ligand-Controlled Magnetic Interactions in Mn<sub>4</sub> Clusters
Published 2009“…Experimentally measured magnetic moments in high magnetic fields show that, upon electron density withdrawal, the main antiferromagnetic exchange constant <i>J</i><sub>1</sub> decreases from −2.2 K for the [Mn<sub>4</sub>(OAc)<sub>4</sub>] cluster to −1.9 K for the [Mn<sub>4</sub>(H<sub>5</sub>C<sub>6</sub>COO)<sub>4</sub>] cluster and −0.6 K for the [Mn<sub>4</sub>(F<sub>3</sub>CCOO)<sub>4</sub>] cluster, while <i>J</i><sub>2</sub> decreases from −1.1 K to nearly 0 K and <i>J</i><sub>3</sub> changes to a small ferromagnetic coupling. …”
-
543
Ligand-Controlled Magnetic Interactions in Mn<sub>4</sub> Clusters
Published 2009“…Experimentally measured magnetic moments in high magnetic fields show that, upon electron density withdrawal, the main antiferromagnetic exchange constant <i>J</i><sub>1</sub> decreases from −2.2 K for the [Mn<sub>4</sub>(OAc)<sub>4</sub>] cluster to −1.9 K for the [Mn<sub>4</sub>(H<sub>5</sub>C<sub>6</sub>COO)<sub>4</sub>] cluster and −0.6 K for the [Mn<sub>4</sub>(F<sub>3</sub>CCOO)<sub>4</sub>] cluster, while <i>J</i><sub>2</sub> decreases from −1.1 K to nearly 0 K and <i>J</i><sub>3</sub> changes to a small ferromagnetic coupling. …”
-
544
-
545
<i>B-MOBILE</i> - A Smartphone-Based Intervention to Reduce Sedentary Time in Overweight/Obese Individuals: A Within-Subjects Experimental Trial
Published 2014“…Average % SED at baseline (72.2%) decreased by 5.9%, 5.6%, and 3.3% [i.e. by mean (95% CI) −47.2(−66.3, −28.2), −44.5(−65.2, −23.8), and −26.2(−40.7, −11.6) min/d] in the 3-, 6-, and 12-min conditions, respectively. …”
-
546
-
547
Overview of study procedures.
Published 2025“…VIDEO and CONTROL were associated with a similar rise in intent to decrease OTC NSAID use (1.92 (SD: 4.41) vs. 1.36 (SD: 3.46), p = 0.150) and a similar decrease in NSAIDs exposure (−32.8% in VIDEO and −36.5% in CONTROL, p = 0.520) 4 weeks post-intervention. …”
-
548
Image_1_Artesunate Alleviates Paclitaxel-Induced Neuropathic Pain in Mice by Decreasing Metabotropic Glutamate Receptor 5 Activity and Neuroinflammation in Primary Sensory Neurons....
Published 2022“…Artesunate normalized paclitaxel-related expression changes in DRG mGluR5, NR1, and GluA2, as well as six paclitaxel related neuroinflammation markers. …”
-
549
-
550
Supplementary Material for: Optimistic Youth: Young Adults Predicted a Faster Decrease in Risk during COVID-19 Emergency State in Portugal
Published 2022“…‘in two weeks’ time’, or ‘in four weeks’ time’) of both risk behaviour and importance of transmission prevention decrease over time. …”
-
551
-
552
Heterologous Immunity Triggered by a Single, Latent Virus in <i>Mus musculus</i>: Combined Costimulation- and Adhesion- Blockade Decrease Rejection
Published 2013“…MHV68 infection was correlated with multimodal immune deviation, which included increased secretion of CXCL9 and CXCL10, and with the expansion of a CD8<sup>dim</sup> T cell population. CD8<sup>dim</sup> T cells exhibited decreased expression of multiple costimulation molecules and increased expression of two adhesion molecules, LFA-1 and VLA-4. …”
-
553
-
554
-
555
-
556
-
557
-
558
A PPARα Promoter Variant Impairs ERR-Dependent Transactivation and Decreases Mortality after Acute Coronary Ischemia in Patients with Diabetes
Published 2010“…Consistent with previous descriptions of PPARα in experimental models and human disease, we describe a novel <em>PPARA</em> promoter SNP that decreases transcriptional activation of <em>PPARA</em> and protects against mortality in diabetic patients after ACS.…”
-
559
-
560